References
- Rydén L Standl E Bartnik M Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 2007 28 1 88 136 17220161
- Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 4 470 512 19074620
- Deacon CF Wamberg S Bie P Hughes TE Holst JJ Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs J Endocrinol 2002 172 2 355 362 11834453
- Cavusoglu E Ruwende C Chopra V Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography Atherosclerosis 2010 210 1 226 231 19944421
- Poornima I Brown SB Bhashyam S Parikh P Bolukoglu H Shannon RP Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circ Heart Fail 2008 1 3 153 160 19727407
- Antoniades C Demosthenous M Tousoulis D Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis Hypertension 2011 58 1 93 98 21518967
- Mason RP Jacob RF Kubant R Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats J Atheroscler Thromb 2011 18 9 774 783 21670556
- Kotseva K Wood D De Backer G De Bacquer D Pyörälä K Keil U EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardio protective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 2009 16 2 121 137 19287307
- Vallance P Leone A Calver A Collier J Moncada S Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Lancet 1992 339 8793 572 575 1347093
- Sibal L Agarwal SC Home PD Boger RH The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease Curr Cardiol Rev 2010 6 2 82 90 21532773
- Yin M Silljé HH Meissner M van Gilst WH de Boer RA Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure Cardiovasc Diabetol 2011 10 85 21955567
- Huisamen B Genis A Marais E Lochner A Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats Cardiovasc Drugs Ther 2011 25 1 13 20 21088878
- Nikolaidis LA Mankad S Sokos GG Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 2004 109 8 962 965 14981009
- Ku HC Chen WP Su MJ DPP4 deficiency preserves cardiac function via GLP-1 signalling in rats subjected to myocardial ischemia/reperfusion Naunyn Schmiedebergs Arch Pharmacol 2011 384 2 197 207 21748358
- Sauvé M Ban K Momen MA Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 2010 59 4 1063 1073 20097729